Download PDF
Semin Thromb Hemost 2014; 40(04): 503-507
DOI: 10.1055/s-0034-1375295
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Role of Complement in Enterohemorrhagic Escherichia coli–Induced Hemolytic Uremic Syndrome

Dorothea Orth-Höller
1   Division of Hygiene and Medical Microbiology, Innsbruck Medical University, Innsbruck, Austria
,
Reinhard Würzner
1   Division of Hygiene and Medical Microbiology, Innsbruck Medical University, Innsbruck, Austria
› Author Affiliations
Further Information

Publication History

Publication Date:
05 May 2014 (online)

    Permissions and Reprints

Abstract

Hemolytic uremic syndrome (HUS), the most common cause of acute renal failure in childhood, is mainly caused by infection with Shiga toxin (Stx)-producing enterohemorrhagic Escherichia coli (EHEC). Besides its cytotoxic activity, Stx has been shown to interact with the complement system. Complement breakdown products have been found in serum of HUS patients suggesting complement activation and in vitro studies have demonstrated that Stx2 directly activates complement leading to formation of terminal complement complex. Furthermore, Stx2 has been found to bind to factor H (FH) resulting in a reduced cofactor activity on the cell surface. Binding of Stx2 has also been shown for other members of the FH family, namely FH-like protein 1 and FH-related protein 1. Both proteins also compete with FH for Stx binding, so that in the presence of FHR-1 less FH is bound to Stx and therefore more is available for endothelial cell protection. In addition, Stx2 has been demonstrated to downregulate the membrane-bound regulator CD59 on the surface of glomerular endothelial and tubulus epithelial cells on protein and at the mRNA level. In conclusion, Stx modulates complement regulator proteins leading to an impaired control and thus to enhanced complement activation. Its implication in the pathogenesis of EHEC-induced HUS in vivo and whether complement blockage might be a therapeutic option still has to be elucidated.

Keywords

hemolytic uremic syndrome - Shiga toxin - complement - factor H family proteins - membrane-bound complement regulators
 

  • References

  • 1 Tarr PI, Gordon CA, Chandler WL. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 2005; 365 (9464) 1073-1086
    PubMedGoogle Scholar
  • 2 Kaplan BS, Meyers KE, Schulman SL. The pathogenesis and treatment of hemolytic uremic syndrome. J Am Soc Nephrol 1998; 9 (6) 1126-1133
    PubMedGoogle Scholar
  • 3 European Centre for Disease Prevention and Control and European Food Safety Authority. Shiga toxin/verotoxin-producing Escherichia coli in humans, food and animals in the EU/EEA, with special reference to the German outbreak strain STEC O104. Stockholm. 2011
    Google Scholar
  • 4 Robert-Koch-Institut Abschließende Bewertung der epidemiologischen Erkentnisse im EHEC O104:H4 Ausbruch, Deutschland 2011
  • 5 Karch H, Tarr PI, Bielaszewska M. Enterohaemorrhagic Escherichia coli in human medicine. Int J Med Microbiol 2005; 295 (6-7) 405-418
    CrossrefPubMedGoogle Scholar
  • 6 Obrig TG. Escherichia coli Shiga toxin mechanisms of action in renal disease. Toxins (Basel) 2010; 2 (12) 2769-2794
    CrossrefPubMedGoogle Scholar
  • 7 Endo Y, Tsurugi K, Yutsudo T, Takeda Y, Ogasawara T, Igarashi K. Site of action of a Vero toxin (VT2) from Escherichia coli O157:H7 and of Shiga toxin on eukaryotic ribosomes. RNA N-glycosidase activity of the toxins. Eur J Biochem 1988; 171 (1-2) 45-50
    CrossrefPubMedGoogle Scholar
  • 8 Zimmerhackl LB, Besbas N, Jungraithmayr T , et al; European Study Group for Haemolytic Uraemic Syndromes and Related Disorders. Epidemiology, clinical presentation, and pathophysiology of atypical and recurrent hemolytic uremic syndrome. Semin Thromb Hemost 2006; 32 (2) 113-120
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med 2009; 361 (17) 1676-1687
    CrossrefPubMedGoogle Scholar
  • 10 Sánchez-Corral P, Melgosa M. Advances in understanding the aetiology of atypical Haemolytic Uraemic Syndrome. Br J Haematol 2010; 150 (5) 529-542
    CrossrefPubMedGoogle Scholar
  • 11 Hofer J, Giner T, Józsi M. Complement factor H-antibody–associated hemolytic uremic syndrome: pathogenesis, clinical presentation, and treatment. Semin Thromb Hemost 2014; 40 (4) 431-443
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Speth C, Würzner R, Stoiber H, Dierich MP. Complement. In: Paul W, , ed. Fundamental Immunology. Philadelphia, PA: Lippincott Williams & Wilkins; 2008: 1047-1078
    Google Scholar
  • 13 Zipfel PF, Skerka C. Complement regulators and inhibitory proteins. Nat Rev Immunol 2009; 9 (10) 729-740
    CrossrefPubMedGoogle Scholar
  • 14 Skerka C, Chen Q, Fremeaux-Bacchi V, Roumenina LT. Complement factor H related proteins (CFHRs). Mol Immunol 2013; 56 (3) 170-180
    CrossrefPubMedGoogle Scholar
  • 15 Zipfel PF, Skerka C, Hellwage J , et al. Factor H family proteins: on complement, microbes and human diseases. Biochem Soc Trans 2002; 30 (Pt 6) 971-978
    PubMedGoogle Scholar
  • 16 Kühn S, Skerka C, Zipfel PF. Mapping of the complement regulatory domains in the human factor H-like protein 1 and in factor H1. J Immunol 1995; 155 (12) 5663-5670
    PubMedGoogle Scholar
  • 17 Heinen S, Hartmann A, Lauer N , et al. Factor H-related protein 1 (CFHR-1) inhibits complement C5 convertase activity and terminal complex formation. Blood 2009; 114 (12) 2439-2447
    CrossrefPubMedGoogle Scholar
  • 18 Giannakis E, Jokiranta TS, Male DA , et al. A common site within factor H SCR 7 responsible for binding heparin, C-reactive protein and streptococcal M protein. Eur J Immunol 2003; 33 (4) 962-969
    CrossrefPubMedGoogle Scholar
  • 19 Józsi M, Oppermann M, Lambris JD, Zipfel PF. The C-terminus of complement factor H is essential for host cell protection. Mol Immunol 2007; 44 (10) 2697-2706
    CrossrefPubMedGoogle Scholar
  • 20 Oppermann M, Manuelian T, Józsi M , et al. The C-terminus of complement regulator Factor H mediates target recognition: evidence for a compact conformation of the native protein. Clin Exp Immunol 2006; 144 (2) 342-352
    CrossrefPubMedGoogle Scholar
  • 21 Soames CJ, Sim RB. Interactions between human complement components factor H, factor I and C3b. Biochem J 1997; 326 (Pt 2) 553-561
    PubMedGoogle Scholar
  • 22 Monnens L, Molenaar J, Lambert PH, Proesmans W, van Munster P. The complement system in hemolytic-uremic syndrome in childhood. Clin Nephrol 1980; 13 (4) 168-171
    PubMedGoogle Scholar
  • 23 Kim Y, Miller K, Michael AF. Breakdown products of C3 and factor B in hemolytic-uremic syndrome. J Lab Clin Med 1977; 89 (4) 845-850
    PubMedGoogle Scholar
  • 24 Robson WL, Leung AK, Fick GH, McKenna AI. Hypocomplementemia and leukocytosis in diarrhea-associated hemolytic uremic syndrome. Nephron 1992; 62 (3) 296-299
    CrossrefPubMedGoogle Scholar
  • 25 Thurman JM, Marians R, Emlen W , et al. Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome. Clin J Am Soc Nephrol 2009; 4 (12) 1920-1924
    CrossrefPubMedGoogle Scholar
  • 26 Ståhl AL, Sartz L, Karpman D. Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome. Blood 2011; 117 (20) 5503-5513
    CrossrefPubMedGoogle Scholar
  • 27 Orth D, Grif K, Khan AB, Naim A, Dierich MP, Würzner R. The Shiga toxin genotype rather than the amount of Shiga toxin or the cytotoxicity of Shiga toxin in vitro correlates with the appearance of the hemolytic uremic syndrome. Diagn Microbiol Infect Dis 2007; 59 (3) 235-242
    CrossrefPubMedGoogle Scholar
  • 28 Friedrich AW, Bielaszewska M, Zhang WL , et al. Escherichia coli harboring Shiga toxin 2 gene variants: frequency and association with clinical symptoms. J Infect Dis 2002; 185 (1) 74-84
    CrossrefPubMedGoogle Scholar
  • 29 Orth D, Khan AB, Naim A , et al. Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome. J Immunol 2009; 182 (10) 6394-6400
    CrossrefPubMedGoogle Scholar
  • 30 Markiewski MM, Lambris JD. The role of complement in inflammatory diseases from behind the scenes into the spotlight. Am J Pathol 2007; 171 (3) 715-727
    CrossrefPubMedGoogle Scholar
  • 31 Cotran RS, Pober JS. Cytokine-endothelial interactions in inflammation, immunity, and vascular injury. J Am Soc Nephrol 1990; 1 (3) 225-235
    PubMedGoogle Scholar
  • 32 Ikeda K, Nagasawa K, Horiuchi T, Tsuru T, Nishizaka H, Niho Y. C5a induces tissue factor activity on endothelial cells. Thromb Haemost 1997; 77 (2) 394-398
    PubMedGoogle Scholar
  • 33 Krisinger MJ, Goebeler V, Lu Z , et al. Thrombin generates previously unidentified C5 products that support the terminal complement activation pathway. Blood 2012; 120 (8) 1717-1725
    CrossrefPubMedGoogle Scholar
  • 34 Morigi M, Galbusera M, Gastoldi S , et al. Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis. J Immunol 2011; 187 (1) 172-180
    CrossrefPubMedGoogle Scholar
  • 35 Poolpol K, Orth-Höller D, Speth C , et al. Interaction of Shiga toxin 2 with complement regulators of the factor H protein family. Mol Immunol 2014; 58 (1) 77-84
    CrossrefPubMedGoogle Scholar
  • 36 Ehrlenbach S, Rosales A, Posch W , et al. Shiga toxin 2 reduces complement inhibitor CD59 expression on human renal tubular epithelial and glomerular endothelial cells. Infect Immun 2013; 81 (8) 2678-2685
    CrossrefPubMedGoogle Scholar
  • 37 Dammermann W, Schipper P, Ullrich S , et al. Increased expression of complement regulators CD55 and CD59 on peripheral blood cells in patients with EAHEC O104:H4 infection. PLoS ONE 2013; 8 (9) e74880
    CrossrefPubMedGoogle Scholar
  • 38 Würzner R, Riedl M, Rosales A, Orth-Höller D. Treatment of enterohemorrhagic Escherichia coli–induced hemolytic uremic syndrome (eHUS). Semin Thromb Hemost 2014; 40 (4) 508-516
    Article in Thieme ConnectPubMedGoogle Scholar